Narjust Florez
MD
Associate Director of the Cancer Care Equity Program and Assistant Professor of Medicine
Dana-Farber Cancer Institute
Harvard Medical School
Sep 14, 2026
Episode
380
Soundcloud
Share
In this special WCLC 2026 episode of Lung Cancer Considered, hosts Dr. Narjust Florez and Dr. Stephen Liu discuss daily highlights from the conference and ask what changes in clinic on Monday.
A ROS1 drug that protects the brain and a first-line combination that could not beat a decade-old standard. Dr. Alexander Drilon brings the first-line ARROS-1 data on zidesamtinib, and Dr. Giannis Mountzios walks us through EVOKE-03, sacituzumab govitecan plus pembrolizumab in PD-L1 high lung cancer.
Guest
Stephen Liu
MD
Chief of Hematology and Oncology
Georgetown University
Alexander Drilon
MD
Chief, Early Drug Development Service
Memorial Sloan Kettering Cancer Center
Professor, Weill Cornell Medical College
Attending Physician, Thoracic Oncology Service
Giannis Mountzios
MD
Director of the Oncology Department and Clinical Trials Unit
Henry Dunant Hospital Center
